Telix Pharmaceuticals Limited Enterprise Value to EBITDA (EV/EBITDA) on August 15, 2025: 65.17

Telix Pharmaceuticals Limited Enterprise Value to EBITDA (EV/EBITDA) is 65.17 on August 15, 2025, a -73.68% change year over year. EV/EBITDA ratio compares the enterprise value to the EBITDA; lower suggests more favorable company valuation.
  • Telix Pharmaceuticals Limited 52-week low Enterprise Value to EBITDA (EV/EBITDA) is 397.70 on August 15, 2025, which is 510.25% above the current Enterprise Value to EBITDA (EV/EBITDA).
  • Telix Pharmaceuticals Limited 52-week low Enterprise Value to EBITDA (EV/EBITDA) is 62.25 on August 15, 2025, which is -4.48% below the current Enterprise Value to EBITDA (EV/EBITDA).
  • Telix Pharmaceuticals Limited average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is 206.97.
Key Data
Date Enterprise Value to EBITDA (EV/EBITDA) Free Cash Flow Yield Dividend Yield Market Capitalization